LncRNA LOXL1-AS1 promotes endometrial cancer progression by sponging miR-28-5p to upregulate RAP1B expression
Authors: Yuhui He
Guanlin Xing
Shengxian Liu
Xiaoliang Yang
Fang Wang
Bingyi Li
Journal: Biomedicine & Pharmacotherapy (2020)
Discipline: PHARMACOLOGY & TOXICOLOGY
Keywords: Endometrial cancer (EC); LOXL1-AS1; Long non-coding RNA; RAP1B; miR-28-5p.
Affiliations: Department of Reproductive Medicine, Luoyang Center Hospital Affiliated to Zhengzhou University, China., Department of Reproductive Medicine, Luoyang Center Hospital Affiliated to Zhengzhou University, China. Electronic address: .

Abstract:  Background: Increasing lncRNAs are found to be involved in the biological process of multiple cancer types. Herein, we aimed to reveal the role of LOXL1-AS1 in endometrial cancer (EC) progression. Methods: Tumor and corresponding normal tissues were obtained from EC patients. Si-LOXL1-AS1 and miR-28-5p inhibitor were transfected to downregulate the expressions of LOXL1-AS1 and miR-28-5p, while miR-28-5p mimics were used to upregulate the miR-28-5p expression. CCK-8 and colony assays were applied to estimate the cell proliferation. Flow cytometry was performed to measure the cell apoptosis. Wound healing and transwell assays were conducted to assess the cell migration and invasion abilities. Informatics analysis was used to explore the relationship among LOXL1-AS1, miR-28-5p and RAP1B. Results: LOXL1-AS1 was found markedly up-regulated in EC tissues and cell lines. LOXL1-AS1 knockdown displayed evident suppression in cell proliferation, migration and invasion, as well as promotion in cell apoptosis. Moreover, the LOXL1-AS1 induced regulatory effects on EC cells were partially reversed by miR-28-5p inhibitor. Mechanistically, LOXL1-AS1 competitively bond to miR-28-5p, resulting in upregulation of RAP1B. Additionally, in vivo study confirmed the findings discovered in vitro. Conclusions: In summary, LOXL1-AS1 exerted oncogenic roles in EC progression by sponging miR-28-5p and thereby upregulating RAP1B. This finding might provide potential targets for EC therapy. 

Retracted: No

PubPeer comments:
 At right: Fig. 5.  SDS-PAGE analysis showing integrity of protein antigen **Pfs25** during stability studies at 4u00b1 1 u00b0C u02da Lane-I= plain Pfs25 antigen; Lane-II, Lane-III, Lane-IV antigen extracted from **gel core liposomes at 10, 30 and 90 Day** respectively. At left: Fig 3 from [Tiwari et al (2009)] ,  SDS PAGE analysis showing integrity of protein antigen **HBsAg** in various liposomal formulations LaneI=plain antigen, Lane-II, Lane-III, Lane-IV antigen extracted from **plain liposomes, gel core liposomes, gel administration medium** .  Contrast-enhanced versions below, for ease of comparison. More similar than one might expect. , 
  Fig. 1. Transmission electron photomicrograph of [A] conventional liposomes [B] gel core liposomes. Two of the conventional liposomes in (A) are more similar than one might expect.  , 
  Fig. 4. Molecular characterization of antigen-(A) SDS-PAGE analysis-Lane A: pure Pfs25, Lane B: encapsulated Pfs25 in gel core liposome Pfs25, Lane C: Pfs25 in conventional liposome; Lane D: Pfs25alum adsorbed formulation. The alternation of the streak directions of the rungs in the molecular-weight ladder at left is an unusual phenomenon.  , 
 #1 Added at the right, Fig 3 from [Jain et al (2009)] :  SDS-PAGE analysis showing structural integrity of release antigen. Lane 1: Marker Proteins(205 kDa myosin, habbit muscle; 97 kDa phoporylase B; 67 kDa bovine serum albumin; 43 kDa; ovalbumin; 29 kDa carbonic anhydrase); Lane 2: native HBsAg; Lane 3: HBsAg released from AB NPs; Lane 4: HBsAg released from ABA NPs; Lane 5: HBsAg released from BAB NPs.  , 
 #3 Fig 4 in full:  Molecular characterization of antigen-(A) SDS-PAGE analysis-Lane A: pure Pfs25, Lane B: encapsulated Pfs25 in gel core liposome Pfs25, Lane C: Pfs25 in conventional liposome; Lane D: Pfs25alum adsorbed formulation. (B) Western blot analysis showing immunoreactivity of antigen in encapsulation process Lane A: pure Pfs25, Lane B: encapsulated Pfs25 in gel core liposome Pfs25, Lane C: Pfs25 in conventional liposome; Lane D: Pfs25alum adsorbed formulation.  Fig 5 of  [Jaganathan Vyas (2006)] :  Western blot analysis showing immunoreactivity of HBsAg during stability studies at 37 u25e6C. Lane 1, plain HBsAg antigen; lane 2, Day 1; lane 3, Day 4; lane 4, Day 7; lane 5, Day 10; lane 6, Day 13; lane 7, Day 16; and lane 8, Day 19.  Unexpected similarity, specially with increased contrast.   , 
 #2 Figure 1, at right, rotated through 180 deg. At left, Fig 1 from [Mahor et al (2007)] ,  Transmission electron microscopic image of DNA loaded cationic transfersomes.  , 
 Fig 1B, gel core liposomes.  Two of the Easter Eggs differ only in scale, with identical internal markings. ,